Clinical Trials Logo

Clinical Trial Summary

- To compare global DNA methylation status between ITP patients and healthy subjects .

- To determine the effect of DNMT3A −448 G/A SNP variant A allele and DNMT3B −149C/T SNP variant T-allele on global DNA methylation in both ITP patients and healthy control subjects.


Clinical Trial Description

Immune thrombocytopenia (ITP), is an immune-mediated acquired disease of adults and children characterized by transient or persistent decrease of the platelet count and, depending upon the degree of thrombocytopenia, increased risk of bleeding (Rodeghiero et al., 2009). International guidelines define thrombocytopenia as a peripheral blood platelet count less than 100 000/uL (Raj, 2017). Platelet count values between 100 000/uL and 150 000/uL are frequently found in apparently healthy people (Adibi et al., 2007) and this threshold reduces the concern over the mild "physiologic" thrombocytopenia associated with pregnancy (Neunert et al., 2011).

Immune thrombocytopenia may be primary or secondary. Primary ITP is a diagnosis of exclusion. Secondary ITP occur due to an underlying diseases/conditions. Causes of secondary ITP include infection (CMV, Helicobacter pylori, HCV, HIV, Varicella zoster), Systemic lupus erythematosus, Antiphospholipid syndrome, Drug-induced, Lymphoproliferative disorders, Post bone marrow transplantation, and Post vaccination (Neunert et al., 2011).

Primary ITP is an acquired autoimmune disease causing both increased platelet destruction and insufficient platelet production. More than one mechanism could contribute to this including autoreactive B lymphocytes, Th1/Tc1 polarization, T-cell-mediated platelet lysis and abnormal circulating Treg cells. Also, DNA methylation may participate in the pathophysiology of ITP (Semple et al., 2010, Wang et al., 2011).

DNA methylation is a heritable, stable, and also reversible way of DNA modification; it can regulate gene expression without changing the nucleotide sequences (Huiyuan et al., 2013). DNA methylation is mediated by DNA methyltransferases (DNMTs). There are five members in DNMT group including DNMT3A and DNMT3B (Okano et al., 1999). DNMT3A and DNMT3B catalyze de novo methylation and it is important in the establishment of DNA methylation patterns within the embryo and during fetal development (Sawalha, 2008).

DNA methylation status takes part in the regulation of immune response, the loss of methylation pattern in immune cells will result in autoimmune disease by inducing aberrant gene expression. ITP is an autoimmune disease with many immune deficiencies with abnormal DNA methylation involved in the disease etiology (Huiyuan et al., 2013). Chen et al., 2011, concluded that aberrant DNA methylation may take part in the pathogenesis of ITP by quantifying the methylcytosine concentration of genomic DNA. They found hypomethylation pattern in CD4 T cells of ITP patients.

DNMT3A, and DNMT3B DNA methyltransferases are encoded by different genes on distinct chromosomes (Sawalha, 2008). There are many single nucleotide polymorphisms (SNPs) in DNMT3A gene which may affect catalytic activity of the DNMT3A enzyme, including -448G/A SNP (Zhao et al., 2012). Twenty-one polymorphisms have been identified in the DNMT3B gene including −149 C/T SNP and −579 G/T SNP (Zhang et al., 2015).

In a previous study in Assiut University Hospital (AbdelKader et al., 2018), the DNMT3A −448 G/A SNP variant A allele was significantly associated with decreased risk of primary ITP, while, DNMT3B −149C/T SNP variant T-allele was significantly associated with nearly double-fold increase in risk of primary ITP. However, the underlying mechanism behind this association was not investigated. Authors recommended to study mRNA expression of DNMT genes, enzymatic activity of DNA methyltransferases, quantification of global methylated DNA, and/or methylation status of methylation-sensitive genes involved in primary ITP pathogenesis to understand this association. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04100876
Study type Observational
Source Assiut University
Contact Mennat-Allah A Mahmoud, physician
Phone 01006044750
Email Mennanaser121993@gmail.com
Status Not yet recruiting
Phase
Start date December 1, 2019
Completion date December 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT05621330 - Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia Phase 3
Active, not recruiting NCT04278924 - A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia Phase 2
Recruiting NCT06148389 - The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects Phase 1
Active, not recruiting NCT04812925 - A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia Phase 3
Recruiting NCT06107582 - Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
Recruiting NCT05371743 - Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP)
Not yet recruiting NCT05311930 - Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients Phase 4
Not yet recruiting NCT05333861 - An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
Completed NCT03102593 - A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP Phase 2
Completed NCT06071520 - Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
Recruiting NCT04949009 - Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)
Terminated NCT04224688 - A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Phase 3
Active, not recruiting NCT04225156 - A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). Phase 3
Completed NCT05551624 - Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine Early Phase 1
Recruiting NCT05422365 - Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults Phase 3
Terminated NCT03275740 - A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 Phase 1
Terminated NCT04596995 - A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Phase 3
Terminated NCT04200456 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Phase 3
Recruiting NCT05653219 - A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids Phase 3
Completed NCT01727232 - Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia N/A